DEPLOYDatabase

Company

Synchron

Synchron is a brain-computer interface (BCI) company developing the Stentrode, a stentrode-based BCI implant that does not require open-brain surgery.

Track SynchronGet notified of verified changes
Founded
2016
HQ
New York, NY, USA
Funding
$200.0M
Models
1

Verified profile

  • 1

    Sources on record

  • 0

    Tracked changes

  • Updated recently

    Last verified change

Overview

Synchron is a brain-computer interface (BCI) company developing the Stentrode, a stentrode-based BCI implant that does not require open-brain surgery. Founded by neurologist Tom Oxley, the company has raised over $345M in total funding including a $200M Series D in 2024. Synchron's COMMAND and SWITCH clinical trials demonstrated no serious device-related adverse events across 6 patients, and the FDA has approved the Stentrode for early feasibility studies. The company is based in New York with origins in Melbourne, Australia.

Verified record

Verified deployments
None on file
Active incidents
None on file

DEPLOY Intelligence

Market intelligence for physical AI

Analyst-grade signals, competitive tracking, and investment context across the global physical AI landscape. Launching 2026.

Current leadership (1)

  • Tom Oxley Founder & CEOreported, not verified

Founders (1)

Safety record

No incidents on record for Synchron.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Full safety record: incidents, sourcing, and exposure data →

Recent coverage

Synchron in third-party press

Peer companies